Cerebral amyloid angiopathy (CAA) is cerebrovascular amyloid deposition. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Research
27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
Section I: Pathophysiology of Stroke. Epidemiology of Stroke. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
According to the World Health Organization (WHO), peripheral and central neurological disorders affect approximately one billion people worldwide. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This study shows that WMHs do not significantly alter gray matter nicotinic signaling in directly connected regions. 5 key findings →
Participants: 39 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Cerebral small vessel disease (CSVD) is a common disease in older people, characterized by damage to intracranial microvessels, leading to cognitive decline, increased risk of stroke, and dementia. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
NCs/CSVD-CN: AUC =0.900, 95% CI: 0.847-0.952. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
With elevated HbA1c, greater LA-derived diol/epoxide ratios were associated with greater WMH volume (β [95% CI] = 0.565 [0.100, 1.030], p = 0.017), lower global BPF (β [95% CI] = -0.476 [-0.903, -0.048], p = 0.029), and poorer memory performance (β [95% CI] = -0.603 [-1.070, -0.136], p = 0.012), such that detrimental associations were observed only in T2DM. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Interactions between endothelial cells and mural cells (pericytes and vascular smooth muscle cells) in the blood vessel wall have recently come into focus as central processes in the regulation of vascular formation, stabilization, remodeling, and function. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Diffusion tensor imaging (DTI) has become one of the most popular MRI techniques in brain research, as well as in clinical practice. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
N-methyl-D-aspartate (NMDA) receptor antagonists have therapeutic potential in numerous CNS disorders ranging from acute neurodegeneration (e.g. stroke and trauma), chronic neurodegeneration (e.g. Parkinson's disease, Alzheimer's disease, Huntington's disease, ALS) to symptomatic treatment (e.g. epilepsy, Parkinson's disease, drug dependence, depression, anxiety and chronic pain). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Age has a powerful effect on enhanced susceptibility to neurodegenerative diseases, including susceptibility to stroke and cognitive impairment (CI) even in optimally healthy individuals. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Several clinical trials have evaluated the potential of antiglutamate drugs to improve outcome following acute ischaemic stroke, but to date, the results of these have been disappointing. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
36/100
The structure and function of the chemicals contributing to the three main peaks seen with 1H NMR spectroscopy, N-acetyl-L-aspartate (NAA), creatine/phosphocreatine (Cr), and choline-containing compounds (Cho) is reviewed and the changes seen with these compounds in various disease states are briefly outlined. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Higher age, female sex, cigarette smoking, elevated blood pressure, and baseline lesion load were associated with small vessel disease progression. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
36/100
Proof that blood-brain barrier failure is key to these conditions could provide a target for new treatments to reduce the effects of vascular disease on the brain and prevent cognitive decline and dementia. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
36/100
Mutations in Notch3 cause CADASIL (cerebral autosomal dominant adult onset arteriopathy), which leads to stroke and dementia in humans. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
36/100
The review focuses on the clinical diagnostic utility of transcranial magnetic stimulation (TMS). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Arterial spin labeling (ASL) is a magnetic resonance (MR) imaging technique used to assess cerebral blood flow noninvasively by magnetically labeling inflowing blood. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Recent studies suggest that a complex, distributed neural network underpins semantic cognition. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Tobacco smoke consists of thousands of compounds including nicotine. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The Notch signalling pathway is evolutionarily conserved and is crucial for the development and homeostasis of most tissues. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The treatment of epileptic seizure disorders is not restricted to the achievement of seizure-freedom, but must also include the management of comorbid medical, neurological, psychiatric and cognitive comorbidities. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Nitric oxide (NO) is an important signaling molecule that is widely used in the nervous system. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Defining the multiple roles of the mechanistic (formerly 'mammalian') target of rapamycin (mTOR) signalling pathway in neurological diseases has been an exciting and rapidly evolving story of bench-to-bedside translational research that has spanned gene mutation discovery, functional experimental validation of mutations, pharmacological pathway manipulation, and clinical trials. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Each year, 10 million people worldwide survive the neurologic injury associated with a stroke. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →